Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Transactional relations between caregiving stress, executive functioning, and problem behavior from early childhood to early adolescence.

Lagasse LL, Conradt E, Karalunas SL, Dansereau LM, Butner JE, Shankaran S, Bada H, Bauer CR, Whitaker TM, Lester BM.

Dev Psychopathol. 2016 Aug;28(3):743-56. doi: 10.1017/S0954579416000286.

2.

Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.

Li M.

J Psychopharmacol. 2016 Aug;30(8):749-70. doi: 10.1177/0269881116654697. Epub 2016 Jul 1. Review.

3.

Counterfactual Reasoning in Non-psychotic First-Degree Relatives of People with Schizophrenia.

Albacete A, Contreras F, Bosque C, Gilabert E, Albiach Á, Menchón JM, Crespo-Facorro B, Ayesa-Arriola R.

Front Psychol. 2016 May 9;7:665. doi: 10.3389/fpsyg.2016.00665. eCollection 2016.

4.

Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study.

Eack SM, Hogarty SS, Bangalore SS, Keshavan MS, Cornelius JR.

J Dual Diagn. 2016;12(1):74-82. doi: 10.1080/15504263.2016.1145778.

PMID:
27089154
5.

Brexpiprazole: so far so good.

Das S, Barnwal P, Winston A B, Mondal S, Saha I.

Ther Adv Psychopharmacol. 2016 Feb;6(1):39-54. doi: 10.1177/2045125315614739. Review.

6.

Test-Retest Reliability and Measurement Invariance of Executive Function Tasks in Young Children With and Without ADHD.

Karalunas SL, Bierman KL, Huang-Pollock CL.

J Atten Disord. 2016 Feb 9. pii: 1087054715627488. [Epub ahead of print]

PMID:
26861156
7.

Comparison of Visuospatial and Verbal Abilities in First Psychotic Episode of Schizophrenia Spectrum Disorder: Impact on Global Functioning and Quality of Life.

Rodriguez M, Spaniel F, Konradova L, Sedlakova K, Dvorska K, Prajsova J, Kratochvilova Z, Levcik D, Vlcek K, Fajnerova I.

Front Behav Neurosci. 2015 Dec 18;9:322. doi: 10.3389/fnbeh.2015.00322. eCollection 2015.

8.

Neuropsychological profile in adult schizophrenia measured with the CMINDS.

van Erp TG, Preda A, Turner JA, Callahan S, Calhoun VD, Bustillo JR, Lim KO, Mueller B, Brown GG, Vaidya JG, McEwen S, Belger A, Voyvodic J, Mathalon DH, Nguyen D, Ford JM, Potkin SG; FBIRN.

Psychiatry Res. 2015 Dec 30;230(3):826-34. doi: 10.1016/j.psychres.2015.10.028. Epub 2015 Oct 26.

PMID:
26586142
9.

The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China.

Shi C, Kang L, Yao S, Ma Y, Li T, Liang Y, Cheng Z, Xu Y, Shi J, Xu X, Zhang C, Franklin DR, Heaton RK, Jin H, Yu X.

Schizophr Res. 2015 Dec;169(1-3):109-15. doi: 10.1016/j.schres.2015.09.003. Epub 2015 Oct 4.

PMID:
26441005
10.

The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis.

Carrión RE, McLaughlin D, Auther AM, Olsen R, Correll CU, Cornblatt BA.

Psychol Med. 2015 Nov;45(15):3341-54. doi: 10.1017/S0033291715001233. Epub 2015 Jul 14.

11.

Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms.

Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF.

Schizophr Bull. 2015 Sep;41(5):1045-54. doi: 10.1093/schbul/sbv089. Epub 2015 Jul 3.

12.

Effort-Based Decision Making: A Novel Approach for Assessing Motivation in Schizophrenia.

Green MF, Horan WP, Barch DM, Gold JM.

Schizophr Bull. 2015 Sep;41(5):1035-44. doi: 10.1093/schbul/sbv071. Epub 2015 Jun 18. Review.

13.

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.

Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC.

Neuropsychopharmacology. 2015 Dec;40(13):3053-60. doi: 10.1038/npp.2015.176. Epub 2015 Jun 19.

14.

Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study.

Pinkham AE, Penn DL, Green MF, Harvey PD.

Schizophr Bull. 2016 Mar;42(2):494-504. doi: 10.1093/schbul/sbv056. Epub 2015 May 4. Erratum in: Schizophr Bull. 2016 Sep;42(5):1304.

PMID:
25943125
15.

A psychometric investigation of "macroscopic" speech measures for clinical and psychological science.

Cohen AS, Renshaw TL, Mitchell KR, Kim Y.

Behav Res Methods. 2016 Jun;48(2):475-86. doi: 10.3758/s13428-015-0584-1.

PMID:
25862539
16.

Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia?

Smucny J, Visani A, Tregellas JR.

Front Psychiatry. 2015 Mar 24;6:43. doi: 10.3389/fpsyt.2015.00043. eCollection 2015. Review. No abstract available.

17.

Probing the Dynamic Updating of Value in Schizophrenia Using a Sensory-Specific Satiety Paradigm.

Waltz JA, Brown JK, Gold JM, Ross TJ, Salmeron BJ, Stein EA.

Schizophr Bull. 2015 Sep;41(5):1115-22. doi: 10.1093/schbul/sbv034. Epub 2015 Apr 1.

18.

Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.

Burdick KE, Ketter TA, Goldberg JF, Calabrese JR.

J Clin Psychiatry. 2015 Mar;76(3):e342-50. doi: 10.4088/JCP.14cs09399.

19.

Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Light GA, Swerdlow NR.

Ann N Y Acad Sci. 2015 May;1344:105-19. doi: 10.1111/nyas.12730. Epub 2015 Mar 9. Review.

20.

Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis.

Carrión RE, Cornblatt BA, McLaughlin D, Chang J, Auther AM, Olsen RH, Javitt DC.

Schizophr Res. 2015 May;164(1-3):1-7. doi: 10.1016/j.schres.2015.01.030. Epub 2015 Feb 23.

Items per page

Supplemental Content

Write to the Help Desk